Early Process Considerations For Novel Protein Therapeutics

Complex protein-based therapies — think antibody-drug conjugates and fusion proteins — don’t play by the same process-engineering rules as small molecules and more traditional biologics. They require developers to see the unforeseen and embrace new roles and responsibilities in sourcing both raw materials and outsourced expertise. 

Successful developers can’t let this winding road slow their time to IND. Check out this Bioprocess Online Live where we discussed early workflow considerations for developers of complex protein-based therapeutics.

Available on-demand thanks to the support of Thermo Fisher Scientific.